Matches in Wikidata for { <http://www.wikidata.org/entity/Q99619125> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q99619125 description "article scientifique publié en 2020" @default.
- Q99619125 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99619125 description "scientific article published on 24 September 2020" @default.
- Q99619125 description "wetenschappelijk artikel" @default.
- Q99619125 description "наукова стаття, опублікована 24 вересня 2020" @default.
- Q99619125 name "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 name "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 type Item @default.
- Q99619125 label "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 label "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 prefLabel "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 prefLabel "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 P1433 Q99619125-6CD0E307-19A6-431B-A0B9-B2ACAE87B3A8 @default.
- Q99619125 P1476 Q99619125-CEEFD085-3C6B-4825-87C9-85D910BF2719 @default.
- Q99619125 P2093 Q99619125-0B9E11B8-AD0F-481A-BA0F-B3D980DA30CD @default.
- Q99619125 P2093 Q99619125-15FE494E-85B7-4BDB-BAD8-1AAC6176CE7A @default.
- Q99619125 P2093 Q99619125-3B468CD4-54CE-4B39-88DE-24C3E3C763DD @default.
- Q99619125 P2093 Q99619125-42EE290C-9A68-407E-81AB-A87230039859 @default.
- Q99619125 P2093 Q99619125-537FD974-D031-49A7-B6B4-F53E5160BBFB @default.
- Q99619125 P2093 Q99619125-54FBA2D6-DD3A-4872-BB88-3187E48F2F57 @default.
- Q99619125 P2093 Q99619125-6A042535-CBBE-4634-A4B0-954920303D31 @default.
- Q99619125 P2093 Q99619125-7E80CB46-5CBA-466B-9728-62E7A60BE8F9 @default.
- Q99619125 P2093 Q99619125-AB7D6A3A-6F5A-4E83-B30D-E4B96F8A8F95 @default.
- Q99619125 P2093 Q99619125-AF3F37E8-43E8-48F5-8EFE-9F4443CE8865 @default.
- Q99619125 P2093 Q99619125-C253F0E6-619B-49A9-A276-02EC21B68C0A @default.
- Q99619125 P2093 Q99619125-D7E285AD-4E56-4DEC-A001-5ABAF4096B0F @default.
- Q99619125 P31 Q99619125-03A241D8-030F-4AAE-83CC-44722D598350 @default.
- Q99619125 P356 Q99619125-866F19DD-2F8D-4F74-966D-418CECB4CEE5 @default.
- Q99619125 P50 Q99619125-36936F0F-F823-4CE4-94D1-1DADA3744045 @default.
- Q99619125 P50 Q99619125-D8F46CFB-FF09-445C-B34A-1195F169EBAE @default.
- Q99619125 P50 Q99619125-FB3C4C1D-16A9-49C1-806E-3DA604173A7E @default.
- Q99619125 P577 Q99619125-ECC04B62-A27C-4E93-916C-F5199D0B77E2 @default.
- Q99619125 P698 Q99619125-F0BD892B-53CF-4006-A361-EDC4354FE317 @default.
- Q99619125 P921 Q99619125-DB64262E-4CE4-4B9C-9F94-C602D909536A @default.
- Q99619125 P932 Q99619125-49C8E64C-CFFD-4E1B-8950-9384F0482F70 @default.
- Q99619125 P356 BJD.19460 @default.
- Q99619125 P698 32969489 @default.
- Q99619125 P1433 Q4970191 @default.
- Q99619125 P1476 "Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study" @default.
- Q99619125 P2093 "D Thaçi" @default.
- Q99619125 P2093 "I Guillemin" @default.
- Q99619125 P2093 "J T O'Malley" @default.
- Q99619125 P2093 "L F Eichenfield" @default.
- Q99619125 P2093 "M A Kamal" @default.
- Q99619125 P2093 "M J Cork" @default.
- Q99619125 P2093 "M P Kosloski" @default.
- Q99619125 P2093 "N M H Graham" @default.
- Q99619125 P2093 "N Patel" @default.
- Q99619125 P2093 "S Boklage" @default.
- Q99619125 P2093 "X Sun" @default.
- Q99619125 P2093 "Z Chen" @default.
- Q99619125 P31 Q13442814 @default.
- Q99619125 P356 "10.1111/BJD.19460" @default.
- Q99619125 P50 Q40296660 @default.
- Q99619125 P50 Q90601276 @default.
- Q99619125 P50 Q90601279 @default.
- Q99619125 P577 "2020-09-24T00:00:00Z" @default.
- Q99619125 P698 "32969489" @default.
- Q99619125 P921 Q268667 @default.
- Q99619125 P932 "8247037" @default.